Publications by authors named "Niklas Beumer"
Article Synopsis
- The study investigates the long-term effects of multiple myeloma and its treatment on the immune system of cancer survivors, finding significant changes even years after being cancer-free.
- Analysis revealed that these survivors have a compromised bone marrow environment, which is linked to ongoing inflammation and the presence of residual myeloma cells, despite the absence of detectable cancer.
- The research suggests that initial cancer treatment leads to lasting "immunological scarring," indicating that some immune system changes may be irreversible.
Tissue adaptation is required for regulatory T (Treg) cell function within organs. Whether this program shares aspects with other tissue-localized immune populations is unclear. Here, we analyzed single-cell chromatin accessibility data, including the transposable element (TE) landscape of CD45 immune cells from colon, skin, adipose tissue, and spleen.
View Article and Find Full Text PDFArticle Synopsis
- Circulating tumor cells (CTCs) are critical for understanding tumor diversity and treatment resistance, but traditional methods often capture low numbers, especially in non-small cell lung cancer (NSCLC).
- This study utilized diagnostic leukapheresis (DLA) on six advanced NSCLC patients to access larger blood volumes and employed a new two-step method to enrich CTCs for analysis.
- The results unveiled 3,363 unique CTC transcriptomes, revealing significant heterogeneity and potential distinct phenotypes, which suggests CTCs can serve as valuable indicators for tumor monitoring and targeted therapies in the future.
The Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) is a cutting-edge technology that enables researchers to assess genome-wide chromatin accessibility and to characterize cell type specific gene-regulatory programs. Recent technological progress allows for using this technology also on the single-cell level. In this article, we describe the whole value chain from the isolation of T cells from murine tissues to a complete bioinformatic analysis workflow.
View Article and Find Full Text PDFObjectives: Immune checkpoint inhibitors (ICI) have significantly improved outcome of patients with advanced NSCLC and recently also showed benefit in early-stage disease. Patients with oligometastatic disease (OMD) harbor limited metastases, resectable primary tumors and derive benefit from treatment with multimodal locally ablative and systemic therapy approaches. Nothing is known about feasibility and efficacy of neoadjuvant ICI in this setting.
View Article and Find Full Text PDFnegative myeloproliferative neoplasms (MPNs) consist of essential thrombocythemia, polycythemia vera, and myelofibrosis. The majority of patients harbor the -activating mutation V617F. JAK2 inhibitors were shown to reduce symptom burden and splenomegaly in MPN patients.
View Article and Find Full Text PDFIntroduction: The prognosis of pancreatic cancer has improved only modestly in recent years. This is partly due to the lack of development in precision oncology including immune oncology in this entity. Rearrangements of the proto-oncogene tyrosine protein kinase ROS1 gene represent driver alterations found especially in lung cancer.
View Article and Find Full Text PDF